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Chitosan is a natural polycationic copolymer consisting of glucosamine and N-acetylglucosamine units. 
The polymer has valuable properties as a biomaterial because it is considered to be biocompatible, 
biodegradable and non-toxic. The purpose of this review article is to provide detailed information about 
thiolated chitosans which are gaining popularity because of their  high mucoadhsiveness and  extended 
drug release properties. The derivatization of the primary amino groups of chitosan with coupling 
reagents bearing thiol functions leads to the formation of thiolated chitosans. Various properties of 
chitosan are improved by the immobilization of thiol groups. Due to the formation of disulfide bonds with 
mucus glycoproteins, mucoadhesiveness is augmented. The permeation of paracellular markers 
through mucosa can be enhanced by utilizing thiolated instead of unmodified chitosan. Moreover, 
thiolated chitosans display in situ gelling features due to the pH-dependent formation of inter- as well as 
intra-molecular disulfide bonds. This latter process provides, strong cohesion and stability of carrier 
matrices, being based on thiolated chitosans. The in situ gel formation within the pH range of 5 to 6.8 
makes the application of thiolated chitosans on vaginal, nasal and ocular mucosa also possible. 












*Corresponding author: Email: saiseenu7@rediffmail.com; Tel: 09242892034
Sreenivas & Pai 
Trop J Pharm Res September 2008; 7 (3) 1078 
INTRODUCTION 
Mucoadhesive drug delivery systems 
Mucoadhesion can be defined as the ability of 
synthetic or biological macromolecules to 
adhere to mucosal tissues such as the 
mucosa of the small intestine. Since the early 
1980s, the concept of mucoadhesion has 
gained considerable interest in 
pharmaceutical technology. If this concept can 
reach its full potential, it might open the door 
for novel, highly efficient dosage forms 
especially for oral drug delivery. 
Mucoadhesive drug delivery systems promise 
several advantages that arise from localization 
at a given target site, prolonged residence 
time at the site of drug absorption, and an 
intensified contact with the mucosa increasing 
the drug concentration gradient
1
 Hence, 
uptake and consequently bioavailability of the 
drug may be increased and frequency of 
dosing reduced with the result that patient 
compliance is improved. Various natural and 
synthetic polymers have been discovered as 
mucoadhesive excipients. Their mucoadhe-
sive properties can be explained by their 
interaction with the glycoproteins of the 
mucus, based mainly on non-covalent bonds 
such as ionic interactions, hydrogen bonds 




The biopolymer chitosan is obtained by 
alkaline deacetylation of chitin, which is one of 
the most abundant polysaccharides in nature. 
Shell wastes of shrimp, lobster and crab are 
the main industrial sources of chitin
3
 Chitosan 
is a polysaccharide consisting of copolymers 
of glucosamine and N-acetylglucosamine. The 
primary amino group accounts for the 
possibility of relatively easy chemical 
modification of chitosan and salt formation 
with acids. At acidic pH, the amino groups are 
protonated, which promotes solubility, 
whereas chitosan is insoluble at alkaline and 
neutral pH
4
. Because of its favorable 
properties, such as enzymatic biodegrade-
ability, non-toxicity and biocom-atibility
3
 
chitosan has received considerable attention 
as a novel excipient in drug delivery systems, 
and has been included in the European 
Pharmacopoeia since 2002. So far, chitosan 
has been utilized in various fields of 
pharmaceutical technology, including the 
formulation of controlled release dosage forms 
such as tablets, gels and microspheres, as 
mucoadhesive and/or permeation enhancing 
excipient for oral, nasal, ocular and buccal 
drug delivery
5-8





Recently, it has been shown that polymers 
with thiol groups provide much higher 
adhesive properties than polymers generally 
considered to be mucoadhesive. The 
enhancement of mucoadhesion can be 
explained by the formation of covalent bonds 
between the polymer and the mucus layer 
which are stronger than non-covalent bonds. 
These thiolated polymers (see Fig. 1), known 
as thiomers, interact with cysteinerich 
subdomains of mucus glycoproteins via 
disulfide exchange reactions
11
 or via simple 
oxidation process as shown in Fig. 2.  
To further enhance the solubility of chitosan 
and to improve its mucoadhesive and/or 
permeation enhancing properties, various 








 and chitosan-EDTA 
conjugates
15
 were developed. A further 
modification is based on the immobilization of 
thiol bearing moieties on the polymeric 
backbone of chitosan. To date, three different 
thiolated chitosan derivatives have been 









These thiolated chitosans have numerous 
advantageous features in comparison to 
unmodified chitosan, such as significantly 
improved mucoadhesive and permeation 
enhancing properties
18-21
. The strong cohesive 
properties of thiolated chitosans make them 
highly suitable excipients for controlled drug 
release dosage forms
19,22
. Moreover, solutions 
of thiolated chitosans display in situ gelling 
properties at physiological pH values
17
. 
It is the aim of this review to provide an 
overview about different thiolated chitosan 
derivatives that have been synthesized so far, 
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as well as their characterization and 
optimization utilizing various in vitro test 
systems. The performance of thiolated 
chitosan in in vivo studies, providing proof of 
their applicability in peroral peptide delivery 
systems, will be discussed as well. 
Synthesis of thiolated chitosans 
The primary amino group at the 2-position 
(Fig. 3) of the glucosamine subunit of chitosan 
is the main target for the immobilization of 
thiol groups. As shown in Fig. 3 sulfhydryl 
bearing agents can be covalently attached to 
this primary amino group via the formation of 
amide or amidine bonds. In case of the 
formation of amide bonds the carboxylic acid 
group of the ligands cysteine and thioglycolic 
acid reacts with the primary amino group of 
chitosan mediated by a water soluble 
carbodiimide
2
. The formation of disulfide 
bonds by air oxidation during synthesis is 
avoided by performing the process at a pH 
below 5. At this pH-range the concentration of 
thiolate anions, representing the reactive form 
for oxidation of thiol groups, is low, and the 
formation of disulfide bonds can be almost 
excluded. Alternatively, the coupling reaction 
can be performed under inert conditions.  
In the case of the formation of amidine bonds, 
2-iminothiolane is used as a coupling 
reagent
19
. It offers the advantage of a simple 
one step coupling reaction. In addition, the 
thiol group of the reagent is protected against 
oxidation because of the chemical structure of 
the reagent. Orientating studies with all these 
thiolated chitosans showed that a degree of 
modification of 25–250 mmol thiol groups per 
gram chitosan leads to the highest 
improvement in the mucoadhesive and 
permeation enhancing properties. The amount 
of immobilized thiol groups in reduced and 
oxidized form can be determined via Ellman’s 
reagent
17
 with and without previous 





PROPERTIES OF THIOLATED CHITOSANS 
Mucoadhesive properties 
The improved mucoadhesive properties of 
thiolated chitosans are explained by the 
formation of covalent bonds between thiol 
groups of the polymer and cysteine rich 
subdomains of glycoproteins in the mucus 
layer
24
. These covalent bonds are supposedly 
stronger than noncovalent bonds such as 
ionic interactions of chitosan with anionic 
substructures of the mucus layer. This theory 
was supported by the results of tensile studies 
with tablets of thiolated chitosans which 
demonstrated a positive correlation between 
the degree of modification with thiol bearing 
moieties and the adhesive properties of the 
polymer
2,20
. These findings were confirmed by 
another in vitro mucoadhesion test system 
where the time of adhesion of tablets on 
intestinal mucosa was determined. The 
contact time of the thiolated chitosan 
derivatives increased with increasing amounts 
of immobilized thiol groups
2,19
. 
With chitosan-thioglycolic acid conjugates a 
5–10-fold increase in mucoadhesion in 
comparison to unmodified chitosan was 
achieved. The mucoadhesive properties of 
chitosan-TBA (chitosan-4-thio-butyl-amidine) 
conjugates were even further improved. One 
explanation for this phenomenon can be given 
by the theory that chitosan-TBA conjugates 
additionally increased mucoadhesive 
properties due to improved ionic interactions 
between the additional cationic amidine 
substructure of the conjugate (see Fig 3) and 
anionic substructures within the mucus layer. 
Tensile studies with chitosan-TBA conjugates 
of low, medium and high molecular mass 
(150, 400 and 600 kDa) furthermore indicated 
that medium molecular mass thiolated 
chitosans displayed relatively, the highest 
mucoadhesiveness. Utilizing a medium 
molecular mass chitosan-TBA conjugate 
displaying 264 mM thiol groups per gram 
polymer led to a more than 100-fold 
improvement in mucoadhesion compared to 
unmodified chitosan. This represents the 
greatest progress made so far in the 





In 1994 Illum et al showed the permeation 
enhancing capabilities of chitosan for the first 
time
6
 Chitosan is able to enhance the 
paracellular route of absorption, which is 
important for the transport of hydrophilic 
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compounds such as therapeutic peptides and 
antisense oligonucleotides across the 
membrane. Various studies carried out on 
Caco-2 cell monolayers demonstrated a 
significant decrease in the transepithelial 
electrical resistance after the addition of 
chitosan
25-27
. The mechanism underlying this 
permeation enhancing effect seems to be 
based on the positive charges of the polymer 
which interact with the cell membrane 
resulting in a structural reorganization of tight 
junction-associated proteins
28
. In the presence 
of the mucus layer, however, this permeation 
enhancing effect is comparatively lower, as 
chitosan cannot reach the epithelium because 
of size limited diffusion and/or competitive 
charge interactions with mucins
29
. 
Nevertheless, these results obtained on Caco-
2 cell monolayers could be confirmed by in 
vivo studies, showing an enhanced intestinal 
absorption of the peptide drug, buserelin, in 




The permeation enhancing effect of chitosan 
can be greatly improved by the immobilization 
of thiol groups. The effect of thiolated 
chitosans has been shown in various 
permeation studies in Ussing type chambers 
using freshly excised intestinal mucosa
18
. The 
uptake of fluorescence-labeled bacitracin, for 
instance, was improved 1.6-fold utilizing 0.5% 
of chitosan-cysteine conjugate instead of 
unmodified chitosan
18
. In another study, the 
permeation enhancing effect of chitosan-TBA, 
in comparison to the permeation enhancing 
effect of unmodified chitosan, was shown. The 
uptake of the cationic marker compound, 
rhodamine-123 was 3-fold higher in the 




The likely mechanism responsible for this 
improved permeation enhancement has been 
attributed to the inhibition of the protein, 
tyrosine phosphatase. This enzyme seems to 
be involved in the opening and closing 
process of the tight junctions. Tyrosine 
phosphatase is responsible for the 
dephosphorylation of tyrosine subunits of 
occludin, representing an essential 
transmembrane protein of the tight junctions. 
When these tyrosine subunits of occludin are 
dephosphorylated, the tight junctions are 
closed. In contrast, when these tyrosine 
subunits are phosphorylated, the tight 
junctions are opened. The inhibition of 
tyrosine phosphatase by compounds such as 
phenylarsine oxide, pervanadate or reduced 
glutathione leads consequently to 
phosphorylation and opening of the tight 
junctions
31-33
. In contrast to the stable but toxic 
tyrosine phosphatase inhibitors phenylarsine 
oxide and pervanadate, the inhibitory effect of 
glutathione is lower as it is rapidly oxidized on 
the cell surface, loosing its inhibitory activity
34
. 
Due to the combination of reduced glutathione 
with thiolated chitosans, however, the 
oxidation of the inhibitor on the membrane can 




Thiolated chitosans as matrices for 
controlled drug release 
Chitosan represents, primarily due to its 
mucoadhesive properties, a valuable tool for 
non-invasive drug delivery
5
. The longer 
residence time of formulations based on 
mucoadhesive polymers at the absorption site 
is believed to contribute to an increased 
absorption rate of the incorporated drug. 
However, such an enhanced bioavailability 
can be achieved only if a controlled release of 
the active agent out of the formulation is 
provided.  
Thiolated chitosans also display, besides their 
strong mucoadhesive and permeation 
enhancing properties, excellent cohesive 
properties. The reduced thiol functions on the 
chitosan backbone enable thiolated chitosans 
not only to form disulfide bonds with mucus 
glycoproteins, but also to form inter- as well as 
intra-molecular disulfide bonds. Such a 
crosslinking of the polymeric chains
20
 results 
in a high stability of drug carrier systems 
based on thiolated chitosans (Fig.4).  
The cohesion and stability of a drug delivery 
system over the intended duration of drug 
liberation is often a substantial requirement for 
a controlled release. The usefulness of 
thiolated chitosans as carrier matrices for 
controlled drug release was demonstrated 
with model drugs, such as clotrimazole
19-22
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and salmon calcitonin
36-37
. Clotrimazole is 
well-established as an antimycotic drug in the 
treatment of vaginal infections. In order to 
improve its therapeutic efficacy, a sustained 
release of the drug over a period of several 
days might be highly beneficial. The release of 
clotrimazole out of matrix tablets based on 
either chitosan-thioglycolic acid conjugate or 
chitosan-TBA conjugate was quantified. Both 
thiolated chitosan tablets remained stable 
during the whole period of the experiment (6 
hours) and no disintegration could be 
observed. However, only the chitosan-TBA 
conjugate was able to guarantee a significant 
delay in drug release, compared to unmodified 
chitosan, leading to a sustained release over 
a much longer time period
19-22
. 
Furthermore, the release profile of salmon 
calcitonin out of matrix tablets based on the 
chitosan-TBA conjugate was determined. A 
pseudo zero order release profile of salmon 
calcitonin over the first 8 hours was observed 
in simulated intestinal fluid. During the 
experiment the tablets swelled continuously, 
maintaining good cohesiveness and releasing 
the active agent via a controlled diffusion 
process. These release studies, in which a 
peptide drug was liberated from a thiolated 
chitosan matrix system, permit information 
concerning the chemical events within the 
formulation to be gained. Strong unintended 
interactions between the polymeric matrix 
system and the peptide drug could be 
excluded, based the according to this 
controlled and sustained release profile
37
. 
Both studies confirm that, controlled drug 
release out of thiolated chitosan drug carrier 
systems can be achieved. 
In situ gelling properties 
Rapid clearance from the site of drug action is 
one important factor that limits the efficacy of 
drugs administered to the ocular, nasal and 
vaginal mucosa. It is widely accepted that 
limiting the clearance by increasing the 
viscosity of a drug formulation will result in 
increased bioavailability of these drugs. A very 
promising strategy to obtain drug formulations 
of sufficient viscosity is based on in situ gel 
formation. The formation of a gel at the site of 
drug delivery combines the advantages of a 
solution, which can be easily administered, 
with the favorable viscoelastic properties of a 
gel, providing a prolonged residence time of 
the formulation. The sol–gel transition occurs 
in the physiological environment as a result of 





 or electrolyte 
concentration
40,41
. Thiolated chitosans display 
in situ gelling properties due to the oxidation 
of thiol groups at physiological pH-values, 
which results in the formation of inter- and 
intramolecular disulfide bonds. This cross-
linking process can be observed within the pH 
range of 5–6.8. 
The in situ gelling behavior of thiolated 
chitosans was characterized in vitro by 
rheological measurements. The sol–gel 
transition of thiolated chitosans at pH 5.5 was 
completed after 2 hours when highly cross-
linked gels were formed. In parallel, a 
significant decrease in the thiol group content 
of the polymers was observed, indicating the 
formation of disulfide bonds
17,19
. The 
rheological properties of unmodified chitosan 
remained constant over the whole observation 
period. Rheological investigation of thiolated 
chitosans furthermore demonstrated a clear 
correlation between the total amount of 
polymer-linked thiol groups and the increase 
in elasticity of the formed gel. The more thiol 
groups were immobilized on chitosan, the 
higher was the increase in elastic modulus in 
solutions of thiolated chitosan
17,19
. 
Thiolated chitosan derivatives, therefore, 
seem to be promising new excipients for liquid 
or semisolid formulations, which should 
stabilize themselves once applied on the site 
of drug delivery. The in situ gel formation 
within the pH range of 5 to 6.8 makes the 
application of thiolated chitosans on vaginal, 
nasal and ocular mucosa plausible. 
 
IN VIVO STUDIES: PROOF OF CONCEPT 
The potential of thiolated chitosans for the oral 
administration of hydrophilic macromolecules 
could meanwhile be shown by various in vivo 
studies
35,36
. As model drug, for instance, 
salmon calcitonin was utilized, which is a 
peptide drug of cationic net charge and a 
molecular mass of 3.2 kDa. Salmon calcitonin 
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is used for the treatment of chronic bone 
diseases
37,42
. It is currently marketed in nasal 
spray and injectable forms, both having the 
drawback of low patient acceptance. A higher 
patient compliance should be achieved by the 
application of an oral delivery system for this 
drug. However, the oral bioavailability thus far 
obtained is too low to permit therapeutic 
employment
43
. Therefore, this peptide was 
regarded as a challenging model drug for 
testing the potential of thiolated chitosans.  
Different drug carrier matrices, comprising 
chitosan-TBA conjugate as substantial 
polymeric excipient and containing equal 
amounts of salmon calcitonin and optionally 
the permeation mediator, reduced glutathione, 
were developed. In order to avoid an 
enzymatic degradation of the peptide drug in 
the gastrointestinal tract, chitosan-enzyme 
inhibitor conjugates were added. All 
compounds were homogenized and directly 
compressed to tablets. To enteric-coated 




 and a chitosan-elastatinal 
conjugate
45 
were added. Furthermore, an 
alternative strategy was evaluated, focusing 
on targeted drug release and absorption in the 
stomach. Tablets targeted to the stomach 
contained chitosan-pepstatin A conjugate
36
 
which should avoid pepsinic digestion of 
salmon calcitonin. In order to prevent 
mucoadhesion in the oral cavity and 
oesophagus, these tablets were coated with a 
triglyceride. The different tablets were orally 
given to rats and the plasma calcium level 
was monitored as a function of time. 
Pharmacological efficacy was calculated on 
the basis of the area under the reduction in 
plasma calcium levels of the oral matrix 
tablets versus intravenous injection. The main 
biofeedback parameters after application of 
the drug carrier matrices for the oral delivery 
of salmon calcitonin are shown in Table 1. In 
vivo studies showed no statistically significant 
(P<0.05) reduction of the plasma calcium level 
caused by salmon calcitonin, which was orally 
given in solution. Furthermore, no significant 
effect was observed after oral administration 
of tablets comprising the peptide drug and 
unmodified chitosan, although the native 
polymer is reported to be mucoadhesive and 
to exhibit permeation enhancing effect for 
hydrophilic macromolecules
46
 (see Table 1). 
Table 1 shows that the presence of the 
chitosan-TBA conjugate is essential for 
calcitonin absorption, since only tablets based 
on, thiolated chitosan caused a decrease in 
plasma calcium level of more than 5% for 
several hours. The increased absorption of 
the peptide, when embedded in a thiolated 
chitosan matrix, occurred due to the 
properties of the polymer derivative: the high 
stability and cohesiveness can provide a 
sustained release of the peptide
47
, while the 
mucoadhesive features should lead to a 
prolonged residence time of the dosage form 
at the site of absorption. Moreover, the 
combination of thiolated chitosan with the 
permeation mediator, reduced glutathione, 
seems to have an impact on the bioresponse 
of orally given calcitonin. The significantly 
higher pharmacological efficacy of thiolated 
chitosan tablets containing glutathione in 
comparison to corresponding tablets without 
glutathione (see Table 1) indicates that 
glutathione contributes to the drug absorption 
process. These results are in good agreement 
with in vitro results demonstrating that 
thiomers show strong permeation enhancing 
effect, which can be further improved by the 
addition of glutathione
31
. Therefore, the high in 
vivo efficacy of thiolated chitosans can be 
additionally raised by the use of glutathione.  
Among all thiolated chitosan formulations, 
stomach targeted tablets based on chitosan-
TBA conjugate with the addition of both 
glutathione and chitosan-pepstatin A 
conjugate, showed the strongest effect. They 
led to a decrease of the plasma calcium level 
of more than 10% for at least 12 hours, thus 
demonstrating the validity of systemic peptide 
delivery via the stomach. Moreover, a faster 
and more reproducible onset of action was 
obtained by this novel approach
35,36
. 
According to these results, the applicability of 
thiolated chitosans for the oral administration 
of other peptide drugs seems also likely and is 
the subject of ongoing studies. 
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FUTURE TRENDS 
Non-invasive peptide delivery 
The incorporation of peptide drugs exhibiting a 
cationic net charge in anionic mucoadhesive 
polymers on the one hand leads to a strong 
reduction in the mucoadhesive properties and, 
on the other hand, may hinder drug release as 
a result of strong ionic interactions between 
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Fig 4: Permeation enhancing effect of 0.5% (m/v) Chitosan-TBA conjugate with 5% (m/v) glutathione (о)  
          and 0.5% (m/v) unmodified chitosan (■) on small intestinal mucosa
21 
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the therapeutic ingredient and the polymeric 
network. Consequently, cationic therapeutic 
peptides or peptidomimetics such as 
calcitonin or desmopressin need to be 
embedded in cationic or non-ionic 
mucoadhesive polymers. As non-ionic 
polymers cannot provide sufficient high 
mucoadhesion and thiolated chitosans display 
comparatively the highest mucoadhesive 
properties among cationic polymers, this type 
of thiomer seems to be a favorable tool for the 
oral administration of cationic hydrophilic 
macromolecules. Apart from oral delivery 
systems thiolated chitosans seem to be useful 
also for other non-invasive routes of peptide 
drug administration. In particular, the nasal, 
vaginal, buccal and ocular mucosas are 
interesting targets. 
Production of micro- and nano-particles 
Microparticles based on chitosan disintegrate 
very rapidly unless they are combined with 
multivalent anionic compounds such as 
sodium sulfate
48
 or alginate leading to 
stabilization by an ionic cross-linking process. 
Due to the addition of such multivalent anionic 
compounds, however, the mucoadhesive 
properties of chitosan are strongly reduced. In 
contrast, microparticles that are based on 
thiolated chitosan do not disintegrate. 
Because of the formation of disulfide bonds 
within the polymeric network, microparticles 
are strongly stabilized
49
. Consequently, a 
controlled drug release out of thiolated 
chitosan microparticles can be provided. In 
contrast to the addition of multivalent anionic 
compounds, the immobilization of thiol groups 
on chitosan leads to strongly improved 
mucoadhesive properties. 
Tissue engineering 
A further interesting application of thiolated 
chitosans is their use in tissue engineering. 
The expanding field of tissue engineering 
applications has accelerated the need for 
materials which are tissue compatible, 
 
Table1: Main biofeedback parameters after oral administration of tablets containing all equal  
 amounts of Salmon calcitonin to rats (n=5) 
 
Tablet composition Maximal reduction of Ca-
level (% of initial value) 
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The share of the basic excipient (written in italic and bold) in each tablet type was of at least 65%. (Adapted form  
Andreas BS et al.
35
 and  Guggi et al.
36
)   
a
Decrease in plasma calcium level was not significant in comparison to  
physiological daily variations in rats. 
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biodegradable and with mechanical properties 
similar to the target tissues. Biodegradable 
and biocompatible polymers have been 
attractive candidates for scaffolding materials 
because they degrade as the new tissues are 
formed, eventually without inflammatory 
reactions or toxic degradation. Recently, Kast 
et al demonstrated the biodegradability of 
thiolated chitosan, paving the way for its use 
as novel scaffold material
50
. Further, studies in 
this direction were performed with L-929 
mouse fibroblasts seeded onto chitosan-
thioglycolic acid sheets. The results of this 
study showed that thiolated chitosan can 
provide a porous scaffold structure 
guaranteeing cell anchorage, proliferation and 
tissue formation in three dimensions
50
. Due to 
the in situ gelling properties, it seems possible 
to provide a certain shape of the scaffold 
material by pouring a liquid thiolated 
chitosan
51
 cell suspension in a mold. 
Furthermore, liquid polymer cell suspensions 
may be applied by injection forming semi-solid 
scaffolds at the site of tissue damage. Since 
low concentrated aqueous solutions of 
thiolated chitosan remain liquid when stored 
under inert conditions and are rapidly gel 
under access of oxygen, they seem to be 
promising candidates for such applications. 
Coating of stents 
Another promising application of thiolated 
chitosans is their use as coating material for 
stents. Polymer-coated drug-eluting stents are 
a potential technique to achieve high local 
tissue concentrations of an effective drug at 
the precise site and at the time of vessel 
injury. First orientating studies demonstrated 
that by simply dipping the stent in a thiolated 
chitosan solution and drying it on air, a stable 
coating could be achieved. During the drying 
process, cross-linking of chitosan by the 
formation of disulfide bonds due to air 
oxidation, takes place. The polymeric network 
is thereby stabilized on the stent. The chitosan 
coating should allow sustained release of 
incorporated drugs such as anti-inflammatory 
agents or agents avoiding cell proliferation. 
Recently, it was shown that stents can be 
successfully coated with thiolated poly(acrylic 
acid) and that sustained release of a model 
peptide drug out of this thiomeric coating can 
be provided. Similar results can be expected 
for thiolated chitosans but have to be verified 
by ongoing studies. 
 
CONCLUSION    
The chemical modification of chitosan via 
derivatization with various reagents bearing 
sulfhydryl functions causes a dramatic change 
in the polymer’s properties. Mucoadhe-
siveness and cohesiveness are strongly 
improved. A comparatively stronger 
permeation enhancing effect is provided which 
can be further raised by the combination of 
thiolated chitosans with the permeation 
mediator, glutathione. Furthermore, thiolated 
chitosans display in situ gelling features and 
facilitate controlled drug release. Due to these 
advantageous features thiolated chitosans 
have been successfully used for peroral 
administration of peptide drugs. They seem to 
represent a promising new generation of 
polymeric excipients, in particular for the non-
invasive administration of hydrophilic 
macromolecular drugs.  
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